Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) showed limited clinical therapeutic efficiency with chemotherapy for its multi-distributed lesions and hard-to-kill leukemia cells deep in the bone marrow. RESULTS: Here, a biomimetic nanosystem (DR@PLip) based on platelet membrane (PM) coating and doxorubici...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Mo, Qiao, Yingyu, Cao, Jie, Ta, La, Ci, Tianyuan, Ke, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195256/
https://www.ncbi.nlm.nih.gov/pubmed/35701846
http://dx.doi.org/10.1186/s12951-022-01491-w
_version_ 1784726928814505984
author Chen, Mo
Qiao, Yingyu
Cao, Jie
Ta, La
Ci, Tianyuan
Ke, Xue
author_facet Chen, Mo
Qiao, Yingyu
Cao, Jie
Ta, La
Ci, Tianyuan
Ke, Xue
author_sort Chen, Mo
collection PubMed
description BACKGROUND: Acute myeloid leukemia (AML) showed limited clinical therapeutic efficiency with chemotherapy for its multi-distributed lesions and hard-to-kill leukemia cells deep in the bone marrow. RESULTS: Here, a biomimetic nanosystem (DR@PLip) based on platelet membrane (PM) coating and doxorubicin (DOX)/ginsenoside (Rg3) co-loading was developed to potentiate the local-to-systemic chemoimmunotherapy for AML. The PM was designed for long-term circulation and better leukemia cells targeting. The participation of Rg3 was proved to enhance the tumor sensitivity to DOX, thus initiating the anti-tumor immune activation and effectively combating the leukemia cells hiding in the bone marrow. CONCLUSIONS: In conclusion, the strategy that combining immediate chemotherapy with long-term immunotherapy achieved improved therapeutic efficiency and prolonged survival, which provided a new perspective for the clinical treatment of AML. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01491-w.
format Online
Article
Text
id pubmed-9195256
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91952562022-06-15 Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia Chen, Mo Qiao, Yingyu Cao, Jie Ta, La Ci, Tianyuan Ke, Xue J Nanobiotechnology Research BACKGROUND: Acute myeloid leukemia (AML) showed limited clinical therapeutic efficiency with chemotherapy for its multi-distributed lesions and hard-to-kill leukemia cells deep in the bone marrow. RESULTS: Here, a biomimetic nanosystem (DR@PLip) based on platelet membrane (PM) coating and doxorubicin (DOX)/ginsenoside (Rg3) co-loading was developed to potentiate the local-to-systemic chemoimmunotherapy for AML. The PM was designed for long-term circulation and better leukemia cells targeting. The participation of Rg3 was proved to enhance the tumor sensitivity to DOX, thus initiating the anti-tumor immune activation and effectively combating the leukemia cells hiding in the bone marrow. CONCLUSIONS: In conclusion, the strategy that combining immediate chemotherapy with long-term immunotherapy achieved improved therapeutic efficiency and prolonged survival, which provided a new perspective for the clinical treatment of AML. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01491-w. BioMed Central 2022-06-14 /pmc/articles/PMC9195256/ /pubmed/35701846 http://dx.doi.org/10.1186/s12951-022-01491-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Mo
Qiao, Yingyu
Cao, Jie
Ta, La
Ci, Tianyuan
Ke, Xue
Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
title Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
title_full Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
title_fullStr Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
title_full_unstemmed Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
title_short Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
title_sort biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195256/
https://www.ncbi.nlm.nih.gov/pubmed/35701846
http://dx.doi.org/10.1186/s12951-022-01491-w
work_keys_str_mv AT chenmo biomimeticdoxorubicinginsenosidecoloadingnanosystemforchemoimmunotherapyofacutemyeloidleukemia
AT qiaoyingyu biomimeticdoxorubicinginsenosidecoloadingnanosystemforchemoimmunotherapyofacutemyeloidleukemia
AT caojie biomimeticdoxorubicinginsenosidecoloadingnanosystemforchemoimmunotherapyofacutemyeloidleukemia
AT tala biomimeticdoxorubicinginsenosidecoloadingnanosystemforchemoimmunotherapyofacutemyeloidleukemia
AT citianyuan biomimeticdoxorubicinginsenosidecoloadingnanosystemforchemoimmunotherapyofacutemyeloidleukemia
AT kexue biomimeticdoxorubicinginsenosidecoloadingnanosystemforchemoimmunotherapyofacutemyeloidleukemia

Ejemplares similares